Novartis releases 2013 Corporate Responsibility Performance Report

August 29, 2014 – Novartis has a strong history of CR activities, and transparent reporting is a central part of our commitment to corporate responsibility. We have publicly reported on our performance in this area since 2000 through our Annual Report and several online and printed materials.

For 2013, we have consolidated information previously published in our separate GRI; Health, Safety and Environment; and United Nations Global Compact reports into a single Corporate Responsibility Performance Report.

This report enhances our transparency in several key …

/by

Sandoz donates 25,000 units of benzathine penicillin to rheumatic heart disease study in Zambia

August 29, 2014 – Life-saving medicines from Sandoz have arrived at the University Teaching Hospital in Lusaka, Zambia. The donated units of benzathine penicillin will support a new rheumatic heart disease study by the Novartis Institutes for BioMedical Research (NIBR). Penicillin prophylaxis is the only way by which new cases of rheumatic heart disease can be prevented.
Read more.

/by

Sandoz Brazil introduces a new option for oncology patients

  • First generic version of oncology medicine bortezomibe in Brazil
  • New therapeutic option for patients suffering from multiple myeloma

São Paulo, August 26, 2014 – Sandoz, the generic pharmaceutical division of Novartis, today announces the market introduction in Brazil of the first generic version of oncology medicine bortezomibe.

Sandoz will distribute and promote bortezomibe in Brazil, based on an agreement with Accord Pharmaceuticals. This will be the first Sandoz medicine marketed in Brazil for treatment of hematologic – as opposed to …

/by

Sandoz donates 25,000 units of benzathine penicillin to rheumatic heart disease study in Zambia

August 21, 2014 – Life-saving medicines from Sandoz have arrived at the University Teaching Hospital in Lusaka, Zambia. The donated units of benzathine penicillin will support a new rheumatic heart disease study by the Novartis Institutes for BioMedical Research (NIBR). Penicillin prophylaxis is the only way by which new cases of rheumatic heart disease can be prevented.

Rheumatic heart disease (RHD) has been practically eradicated in wealthy nations, but in the developing world the disease remains a major cause of morbidity and mortality, particularly in children …

/by

Sandoz receives first aproval in Latin America for innovative respiratory inhaler Airflusal® Forspiro®

  • Mexico’s Health Authority (COFEPRIS) grants marketing authorization for Airflusal® Forspiro®
  • Approval for 50-100mg, 50-250mg and 50-500mg dosage forms
  • Product to be branded IrFlosolTM Forspiro® in Mexico
  • Airflusal® Forspiro® already launched in four European countries as well as in South Korea

Holzkirchen, August 20, 2014 – Sandoz announces today that the Mexican Health Authority (COFEPRIS) has granted Sandoz marketing authorization for Airflusal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic …

/by

Sandoz Germany launches innovative new topical therapy for erectile dysfunction, a leading urological disorder

  • Sandoz Germany launches Vitaros®, an innovative new patent-protected therapy for leading urology disorder erectile dysfunction (ED)
  • First topical therapy approved for treatment of ED, characterized by ease of use, rapid onset and high tolerability
  • Launch in Sandoz’s largest EU market further demonstrates company commitment to meeting unmet medical need across key therapeutic areas

Holzkirchen, August 18, 2014 – Sandoz, the generic pharmaceuticals division of Novartis, today announces the launch in Germany of Vitaros®, an innovative new …

/by

Sandoz Sweden launches innovative new topical therapy for erectile dysfunction,a leading urological disorder

  • Sandoz Sweden launches Vitaros®, an innovative new patent-protected therapy for leading urology disorder erectile dysfunction (ED)
  • First topical therapy approved for treatment of ED, characterized by ease of use, rapid onset and high tolerability
  • Launch demonstrates Sandoz commitment to meeting unmet medical need across key therapeutic areas, including Women’s and Men’s Health

Holzkirchen, August 4, 2014 – Sandoz, the generic pharmaceuticals division of Novartis, today announces the launch in Sweden of Vitaros®, an innovative new topical …

/by